Tracers / [177Lu]Lu-SibuDAB
[177Lu]Lu-SibuDAB
Also written as [Lu-177]Lu-SibuDAB
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- PSMA-targeting small-molecule ligand with albumin-binding moiety
- Target / mechanism
- Prostate-specific membrane antigen (PSMA) PMID 39894880
- Clinical application
- Radioligand therapy of metastatic castration-resistant prostate cancer; dosimetry study PMID 39894880
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — Elysia-Raytest | vendor cassette | — | — | — | SibuDAB Diverchim CDMO, Roissy-en-France, France | 39894880 2025 Eur J Nucl Med Mol Imaging The radiolabelling was performed on an automated radiosynthesis module (Gaia V2 and Luna, Elysia-Raytest, Straubenhardt, Germany) with cassettes and reagent kits for 177Lu-labeling (Advanced biochemical compounds ABX, Radeberg, Germany). |
Need this precursor?We can point you to suppliers for [177Lu]Lu-SibuDAB, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.